FibrosisTissue transglutaminase (TG2) plays a central role in fibrosis by recruiting TGF-β, disturbing extracellular matrix protein homeostasis, and supporting fibroblast proliferation.
Zedira scientists developed a new class of tissue transglutaminase inhibitors with a reversible mode-of-inhibition that are potent and selective. The novel compounds were optimized for in vivo oral bioavailability and favorable pharmacokinetic profiles. Please refer to the respective press release.
Proprietary drug candidates are therefore available to target dysregulated active TG2 in fibrotic disorders of the lung, kidney, and liver. Zedira offers partnerships for the clinical development of these drug candidates.
In July 2022, Dr. Falk Pharma and Zedira announced the start of the phase 2a proof-of-concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD) (press release).
Moreover, Zedira is planning to expand its global leadership position in the transglutaminase field by investing in follow-up drug discovery projects.
Interested? Please, do not hesitate to contact us: contact@zedira.com
Besuch des Bundesministers für Wirtschaft und Klimaschutz Dr. Robert Habeck bei der Zedira 
Discover Our New Catalogue Edition and Dive into the World of Transglutaminases! 
Successful ISO9001:2015 recertification 
Dr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease 
Dr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie 
Reversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis 
Transcriptomic analysis of the efficacy of TG2-inhibitor trials and human intestinal organoids modelling Celiac disease pathogenesis 
Transglutaminase antibodies and neurological manifestations of gluten sensitivity 
Design of Oral FXIIIa Blockers as Safer Anticoagulants Mission Impossible? 
Microbial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering 
Tridegin as FXIIIa inhibitor 
Microbial transglutaminase: from discovery to market 
Tissue transglutaminase inhibitors 
Tissue transglutaminase in Alzheimers Disease 
Factor XIIIa: novel target for anticoagulation? 
Microbial transglutaminase for site-specific protein conjugation